Marinus Pharma (MRNS) Reports Q2 Loss of $0.46
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Marinus Pharmaceuticals (MRNS) PT Raised to $3 at Jefferies
August 10, 2016 8:28 AM EDTJefferies analyst Brian Abrahams reiterated a Buy rating and boosted his price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $3.00 (from $2.50).
Abrahams commented, "Though it has taken some time for ganaxolone to find its optimal indications, based on its GABA mechanism, and promising data from... More
